Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
October 03, 2024 16:01 ET
|
Abivax
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris:...
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
May 21, 2024 08:00 ET
|
Morphic Therapeutic
in vivo video presented at DDW 2024 show small molecule α4β7 inhibition rapidly increases rolling velocity & flux of B cells similar to antibodies
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX
April 15, 2024 14:12 ET
|
The Rosen Law Firm PA
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant...
ROSEN, A TOP RANKED LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX
April 08, 2024 16:48 ET
|
The Rosen Law Firm PA
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant...
Abivax reports 2023 financial results and operational update
April 02, 2024 02:30 ET
|
Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Licence exclusive avec Erganeo pour EVerGel, premier candidat médicament d’EVerZom, un traitement révolutionnaire des fistules et de la fibrose du tube digestif.
March 05, 2024 03:10 ET
|
Everzom
Licence exclusive avec Erganeo pour EVerGel, premier candidat médicament d’EVerZom, un traitement révolutionnaire des fistules et de la fibrose du tube digestif. Cette nouvelle licence mondiale est...
Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.
March 05, 2024 03:10 ET
|
Everzom
Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract. This new worldwide license...
Crohn's Disease Treatment Drug Market is Expected to Showcase a Significant Growth During Study Period (2019–2032) | DelveInsight
February 06, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Crohn's Disease Treatment Drug Market is Expected to Showcase a Significant Growth During Study Period (2019–2032) | DelveInsight The Crohn's...
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
February 02, 2024 02:30 ET
|
Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...